Screening for Colorectal Cancer in the United States: Correlates and Time Trends by Type of Test.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
23
12
2020
revised:
19
03
2021
accepted:
21
05
2021
pubmed:
6
6
2021
medline:
25
2
2022
entrez:
5
6
2021
Statut:
ppublish
Résumé
It is strongly recommended that adults aged 50-75 years be screened for colorectal cancer. Recommended screening options include colonoscopy, sigmoidoscopy, CT colonography, guaiac fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), or the more recently introduced FIT-DNA (FIT in combination with a stool DNA test). Colorectal cancer screening programs can benefit from knowledge of patterns of use by test type and within population subgroups. Using 2018 National Health Interview Survey (NHIS) data, we examined colorectal cancer screening test use for adults aged 50-75 years ( In 2018, an estimated 66.9% of U.S. adults aged 50-75 years had a colorectal cancer screening test within recommended time intervals. However, the prevalence was less than 50% among those aged 50-54 years, those without a usual source of health care, those with no doctor visits in the past year, and those who were uninsured. The test types most commonly used within recommended time intervals were colonoscopy within 10 years (61.1%), FOBT or FIT in the past year (8.8%), and FIT-DNA within 3 years (2.7%). After age-standardization to the 2010 census population, the percentage up-to-date with CRC screening increased from 61.2% in 2015 to 65.3% in 2018, driven by increased use of stool testing, including FIT-DNA. These results show some progress, driven by a modest increase in stool testing. However, colorectal cancer testing remains low in many population subgroups. These results can inform efforts to achieve population colorectal cancer screening goals.
Sections du résumé
BACKGROUND
It is strongly recommended that adults aged 50-75 years be screened for colorectal cancer. Recommended screening options include colonoscopy, sigmoidoscopy, CT colonography, guaiac fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), or the more recently introduced FIT-DNA (FIT in combination with a stool DNA test). Colorectal cancer screening programs can benefit from knowledge of patterns of use by test type and within population subgroups.
METHODS
Using 2018 National Health Interview Survey (NHIS) data, we examined colorectal cancer screening test use for adults aged 50-75 years (
RESULTS
In 2018, an estimated 66.9% of U.S. adults aged 50-75 years had a colorectal cancer screening test within recommended time intervals. However, the prevalence was less than 50% among those aged 50-54 years, those without a usual source of health care, those with no doctor visits in the past year, and those who were uninsured. The test types most commonly used within recommended time intervals were colonoscopy within 10 years (61.1%), FOBT or FIT in the past year (8.8%), and FIT-DNA within 3 years (2.7%). After age-standardization to the 2010 census population, the percentage up-to-date with CRC screening increased from 61.2% in 2015 to 65.3% in 2018, driven by increased use of stool testing, including FIT-DNA.
CONCLUSIONS
These results show some progress, driven by a modest increase in stool testing. However, colorectal cancer testing remains low in many population subgroups.
IMPACT
These results can inform efforts to achieve population colorectal cancer screening goals.
Identifiants
pubmed: 34088751
pii: 1055-9965.EPI-20-1809
doi: 10.1158/1055-9965.EPI-20-1809
pmc: PMC8338800
mid: NIHMS1714119
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1554-1565Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
MMWR Morb Mortal Wkly Rep. 2020 Mar 13;69(10):253-259
pubmed: 32163384
Gastroenterology. 2018 Nov;155(5):1383-1391.e5
pubmed: 30031768
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):196-200
pubmed: 20056638
Open J Epidemiol. 2013 Feb;3(1):20-24
pubmed: 24027657
Ann Intern Med. 2008 Nov 4;149(9):627-37
pubmed: 18838716
J Natl Cancer Inst. 2020 Mar 1;112(3):305-313
pubmed: 31187126
JAMA. 2017 Apr 25;317(16):1631-1641
pubmed: 28444278
Vital Health Stat 2. 2018 Aug;(175):1-22
pubmed: 30248016
Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):895-904
pubmed: 22490320
Cancer Causes Control. 2016 Jul;27(7):881-7
pubmed: 27228991
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):768-76
pubmed: 18381474
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):758-67
pubmed: 18381467
Can Fam Physician. 2007 Jul;53(7):1192-7
pubmed: 17872816
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
N Engl J Med. 2014 Jul 10;371(2):187-8
pubmed: 25006736
Biometrics. 1999 Jun;55(2):652-9
pubmed: 11318229
Cancer. 2019 Dec 1;125(23):4203-4209
pubmed: 31479529
JAMA. 2016 Jun 21;315(23):2576-94
pubmed: 27305422
Prev Med. 2018 Jul;112:199-206
pubmed: 29729288
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):777-84
pubmed: 18381476
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):344-50
pubmed: 26843520
CA Cancer J Clin. 2020 Jul;70(4):283-298
pubmed: 32583884
Prev Med. 2004 Jul;39(1):27-35
pubmed: 15207983
Vital Health Stat 2. 2014 Apr;(165):1-53
pubmed: 24775908
J Diabetes. 2014 Sep;6(5):451-61
pubmed: 24393518
Fam Pract. 2011 Dec;28(6):683-8
pubmed: 21566004
MMWR Morb Mortal Wkly Rep. 2017 Mar 03;66(8):201-206
pubmed: 28253225
Am J Public Health. 2014 Jun;104(6):982-6
pubmed: 24825195